Re: Schelfhout J, Bonafede M, Cappell K, et al. Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. Curr Med Res Opin. 2020; 36(1):33–41. Schelfhout J, Brown H, House JA, Raval AD. Cytomegalovirus infection and associated hospitalization and costs among individuals undergoing allogeneic hematopoietic stem cell transplant. Curr Med Res Opin. 2020;36(1):43

Umit E.G.Kara O.Adiguzel C.2024-06-122024-06-1220200300-7995https://doi.org/10.1080/03007995.2020.1729109https://hdl.handle.net/20.500.14551/16243[No abstract available]en10.1080/03007995.2020.1729109info:eu-repo/semantics/openAccessGanciclovir; Valaciclovir; Virus Dna; Acute Leukemia; Adult; Aged; Allogeneic Hematopoietic Stem Cell Transplantation; Cytomegalovirus Infection; Female; Hospital Readmission; Hospitalization Cost; Human; Infection Prevention; Letter; Lymphoma; Major Clinical Study; Male; Myeloablative Conditioning; Myeloma; Nonhuman; Reduced Intensity Conditioning; Retrospective Study; Survival; Virus Reactivation; Cost; Cytomegalovirus; Cytomegalovirus Infection; Hematopoietic Stem Cell Transplantation; Hospitalization; Costs And Cost Analysis; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Hospitalization; HumansRe: Schelfhout J, Bonafede M, Cappell K, et al. Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. Curr Med Res Opin. 2020; 36(1):33–41. Schelfhout J, Brown H, House JA, Raval AD. Cytomegalovirus infection and associated hospitalization and costs among individuals undergoing allogeneic hematopoietic stem cell transplant. Curr Med Res Opin. 2020;36(1):43–50.Letter3646072-s2.0-8508304244632090625Q2